Login to Your Account



Other News To Note


Friday, July 20, 2012
• Ligand Pharmaceuticals Inc., of San Diego, said partner Pfizer Inc., of New York, reported that the European Medicines Agency accepted for review the marketing authorization application for bazedoxifene/conjugated estrogens (BZA/CE), under review for use in postmenopausal women with a uterus for treating estrogen deficiency symptoms and treating osteoporosis in women at risk of fracture. Pfizer expects a decision in 2013.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription